Side-by-side comparison of AI visibility scores, market position, and capabilities
HeartFlow creates AI-powered, non-invasive 3D models of coronary arteries from CT scans to guide treatment of coronary artery disease, with FDA clearance and coverage from major insurers including Cigna.
HeartFlow, Inc. is a Redwood City, California–based medical technology company founded in 2011 that applies artificial intelligence to cardiac imaging to transform the diagnosis and management of coronary artery disease (CAD). Its flagship HeartFlow FFRCT Analysis generates a personalized, color-coded 3D model of a patient's coronary arteries from a standard CT scan, calculating fractional flow reserve values non-invasively to identify which blockages actually restrict blood flow. The technology is backed by more than 600 peer-reviewed publications and has helped clinicians manage over 400,000 patients worldwide.
Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.